Oclacitinib-13C-d3
- CAS No.
- 2750534-84-8
- Chemical Name:
- Oclacitinib-13C-d3
- Synonyms
- Oclacitinib-13C-d3
- CBNumber:
- CB46197689
- Molecular Formula:
- C15H20D3N5O2S
- Molecular Weight:
- 341.45
- MDL Number:
- MOL File:
- 2750534-84-8.mol
- MSDS File:
- SDS
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| NFPA 704 |
|
Oclacitinib-13C-d3 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 28808 | Oclacitinib-13C-d3 ≥99%deuteratedforms(d1-d3) | 2750534-84-8 | 500μg | $267 | 2026-04-30 | Buy |
| Cayman Chemical | 28808 | Oclacitinib-13C-d3 ≥99%deuteratedforms(d1-d3) | 2750534-84-8 | 1mg | $505 | 2026-04-30 | Buy |
| ChemScene | CS-0311277 | Oclacitinib-13C-d3 | 1mg | $585 | 2026-06-04 | Buy | |
| aablocks | AA01XHIQ | Oclacitinib-13C-d3 ≥99%deuteratedforms(d1-d3) | 2750534-84-8 | 1mg | $505 | 2026-06-01 | Buy |
Oclacitinib-13C-d3 Chemical Properties, Uses, Production
Description
Oclacitinib-13C-d3 is intended for use as an internal standard for the quantification of oclacitinib (Item No. 18722) by GC- or LC-MS. Oclacitinib is an inhibitor of the JAK family kinases JAK1, JAK2, JAK3, and TYK2 (IC50s = 10, 18, 99, and 84 nM, respectively).1 It is selective for JAK kinases over a panel of 38 additional kinases at 1 μM. Oclacitinib inhibits LPS-induced increases in IL-12 and TNF-α levels in murine bone marrow-derived dendritic cells (BMDCs) in a concentration-dependent manner.2 Topical administration of oclacitinib (0.1, 0.25, and 0.5%) reduces scratching behavior and ear edema, as well as decreases levels of IL-1β, IL-4, and IL-6 in ear skin, in a mouse model of allergic dermatitis induced by toluene-2,3-diisocyanate (TDI). Formulations containing oclacitinib have been used in the treatment of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs.WARNING This product is not for human or veterinary use.
References
[1] A. J. GONZALES. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy[J]. Journal of veterinary pharmacology and therapeutics, 2014, 37 4: 317-324. DOI: 10.1111/jvp.12101
[2] TOMOKI FUKUYAMA. Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.[J]. Journal of Pharmacology and Experimental Therapeutics, 2015, 354 3: 394-405. DOI: 10.1124/jpet.115.223784
Oclacitinib-13C-d3 Preparation Products And Raw materials
Raw materials
Preparation Products
Oclacitinib-13C-d3 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Hongye Biotechnology Co. Ltd | 400-9205774 400-920-5774 | sales@glpbio.cn | China | 6705 | 58 |
| ChemeGen(Shanghai) Biotechnology Co.,Ltd. | 18818260767 | sales@chemegen.com | China | 11123 | 58 |
| CHINA ISOTOPE CO., LIMITED | 02151600108 13062666369 | info@isotopechem.com | China | 4721 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| TLC Pharmaceutical Standards Ltd. | 18012923235 | chinasales04@tlcstandards.com.cn | China | 8143 | 58 |
